Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of FGFR Alterations and Activation in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 2 Dec 2024

Eisner Joel R, de Jong Florus C, Shibata Yoichiro, Mayhew Gregory M, Davison James M, Carcione Jenna, Pappan Kirk L, Thomas Shibu, Triantos Spyros, Santiago-Walker Ademi, Baig Mahadi, Milburn Michael V, Beebe Kirk D, Zuiverloon Tahlita C M

Abstract excerpt

PURPOSE: The Genomic Analysis of High-Risk Non-Muscle-Invasive Bladder Cancer (GARNER) study investigated FGFR alteration (ALT) frequency and the clinical outcome relationship with Bacillus Calmette-Guérin (BCG) treatment in high-risk non-muscle-invasive bladder cancer (HR-NMIBC). An FGFR predictive response signature (FGFR-PRS) was discovered that identifies patients with an activated FGFR pathway who could...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BCG Vaccine
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Neoplasm Invasiveness

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Receptors, Fibroblast Growth Factor

Share to Treatment Outcome

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 39325014
DOI: 10.1158/1078-0432.CCR-24-2015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of FGFR Alterations and Activation in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.PMID 39325014Read ↗

A place for precision medicine in bladder cancer: targeting the FGFRs.Semantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.Semantic proximity Read ↗

An integrated molecular classification system identifies distinct prognostic clusters of non-muscle-invasive bladder cancer.Semantic proximity Read ↗

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.Semantic proximity Read ↗

The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerSemantic proximity Read ↗

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.Semantic proximity Read ↗

Targeting FGFR in bladder cancer: ready for clinical practice?Semantic proximity Read ↗

Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy.Semantic proximity Read ↗

Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images.Semantic proximity Read ↗

Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.Semantic proximity Read ↗

Prognostic Factors of Non-Muscle Invasive Bladder Cancer: A Study Based on Next-generation SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.